Login to Your Account



'Breakthrough' Approvals Ahead?

Endo Phase III Turns Focus To Competitive Pain Market

By Randall Osborne


Monday, December 24, 2007
Endo Pharmaceuticals Inc.'s happy news last week from an interim analysis of its Phase III trial with oral Rapinyl - licensed in North America from the Swiss firm Orexo AB - for breakthrough cancer pain put the spotlight on an $800 million market where the competition grows ever fiercer. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription